Literature DB >> 21267045

Neurotoxicity of subarachnoid preservative-free S(+)-ketamine in dogs.

Lyvia Maria R S Gomes1, João Batista S Garcia, José S Ribamar, Ana Gisélia Portela Nascimento.   

Abstract

BACKGROUND: Subarachnoid S(+)-ketamine is a matter of much debate as the results regarding its toxicity are contradictory.
OBJECTIVES: Our objective was to investigate possible histopathological alterations after subarachnoid administration of different doses of preservative-free S(+)-ketamine to dogs. STUDY
DESIGN: A randomized, blind, prospective experimental study.
SETTING: Center for Research on Pain at the Federal University of Maranhão, Brazil.
METHODS: Sixteen adult mongrel dogs of both sexes, each weighing 11 to 20 kg were divided into 3 groups: Group I (n=6), 0.7 mg/kg-1 S(+)-ketamine; Group II (n=6), 0.5 mg/kg-1 S(+)-ketamine, and a control group, Group III, (n=4), 0.9% NaCl. All substances were administered in one mL volume doses. The animals were kept in captivity for 2 weeks; after this period, they were put down and lumbar and sacral portions of the spinal cords were removed for histological examination using conventional light microscopy.
RESULTS: There were histological alterations in the spinal cords of the test subjects in the control group. Comparison showed significant histological abnormalities in Groups I and II when compared to the control group, including gliosis, axonal edema, central chromatolysis, lymphocyte infiltration and fibrous thickening of the dura mater. LIMITATIONS: Test subjects received only a single dose each. The observation period was not very long, less than a month.
CONCLUSIONS: Subarachnoid administration of S(+)-ketamine without preservative caused histological lesions on the spinal cord and meninges in the dogs studied. S(+)-ketamine should not be given to clinical patients in this way until further evaluation of the significance of this toxicity has been conducted.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21267045

Source DB:  PubMed          Journal:  Pain Physician        ISSN: 1533-3159            Impact factor:   4.965


  4 in total

Review 1.  Consensus Guidelines on the Use of Intravenous Ketamine Infusions for Chronic Pain From the American Society of Regional Anesthesia and Pain Medicine, the American Academy of Pain Medicine, and the American Society of Anesthesiologists.

Authors:  Steven P Cohen; Anuj Bhatia; Asokumar Buvanendran; Eric S Schwenk; Ajay D Wasan; Robert W Hurley; Eugene R Viscusi; Samer Narouze; Fred N Davis; Elspeth C Ritchie; Timothy R Lubenow; William M Hooten
Journal:  Reg Anesth Pain Med       Date:  2018-07       Impact factor: 6.288

2.  In vitro dose-dependent inhibition of the intracellular spontaneous calcium oscillations in developing hippocampal neurons by ketamine.

Authors:  Lining Huang; Yue Liu; Pei Zhang; Rongtian Kang; Ya Liu; Xuze Li; Lijun Bo; Zhenming Dong
Journal:  PLoS One       Date:  2013-03-28       Impact factor: 3.240

3.  Inhibition of acetylcholinesterase modulates NMDA receptor antagonist mediated alterations in the developing brain.

Authors:  Ivo Bendix; Meray Serdar; Josephine Herz; Clarissa von Haefen; Fatme Nasser; Benjamin Rohrer; Stefanie Endesfelder; Ursula Felderhoff-Mueser; Claudia D Spies; Marco Sifringer
Journal:  Int J Mol Sci       Date:  2014-03-03       Impact factor: 5.923

4.  Impact of ketamine on learning and memory function, neuronal apoptosis and its potential association with miR-214 and PTEN in adolescent rats.

Authors:  Ji Wang; Min Zhou; Xiaobin Wang; Xiaoling Yang; Maohua Wang; Chunxiang Zhang; Shuzhi Zhou; Ni Tang
Journal:  PLoS One       Date:  2014-06-10       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.